KALA BIO AI Stock Analysis
Want to see KALA full AI Analyst Report?
KALA BIO (KALA) AI Stock Analysis
KALA BIO
(NASDAQ:KALA)
The score is pressured primarily by very weak financial performance (near-zero revenue, ongoing losses, and significant cash burn) and strongly bearish technical signals (price well below moving averages with negative momentum). Corporate events are mixed, with delisting risk offsetting a positive distribution agreement, while valuation is constrained by loss-making status and no dividend support.
KALA BIO (KALA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $3.31M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.52M
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- 2.20
- Revenue Growth
- ―
- EPS Growth
- 78.25%
- Country
- US
- Employees
- 6
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
KALA BIO Business Overview & Revenue Model
Company Description
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating pa...
KALA BIO Financial Statement Overview
Summary
Overall financial quality is weak: revenue is effectively near zero, losses remain substantial, and cash burn is heavy (TTM free cash flow around -$19.9M). The main offset is an improved balance sheet with debt reduced to $0 and positive equity, which lowers insolvency risk but does not solve the ongoing liquidity dependence on external funding.
Income Statement
8Very NegativeBalance Sheet
46NeutralCash Flow
12Very Negative| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 3.89M | 11.24M |
| Gross Profit | -54.00K | 0 | -259.00K | -303.00K | 1.33M | 7.14M |
| EBITDA | -8.79M | -23.39M | -32.47M | -36.08M | -37.02M | -133.25M |
| Net Income | -10.08M | -26.98M | -38.51M | -42.20M | -44.82M | -142.60M |
Balance Sheet | ||||||
| Total Assets | 10.58M | 9.49M | 55.48M | 55.95M | 86.82M | 139.43M |
| Cash, Cash Equivalents and Short-Term Investments | 7.23M | 7.56M | 51.18M | 50.90M | 70.50M | 92.14M |
| Total Debt | 0 | 0 | 32.25M | 36.32M | 42.95M | 80.19M |
| Total Liabilities | 1.54M | 2.49M | 43.15M | 48.45M | 67.85M | 122.62M |
| Stockholders Equity | 9.04M | 7.00M | 12.33M | 7.50M | 18.97M | 16.80M |
Cash Flow | ||||||
| Free Cash Flow | -19.86M | -31.99M | -29.59M | -28.54M | -79.22M | -109.12M |
| Operating Cash Flow | -19.86M | -31.99M | -29.38M | -27.93M | -78.91M | -108.23M |
| Investing Cash Flow | -15.00K | -15.00K | -208.00K | -429.00K | 62.72M | 70.80M |
| Financing Cash Flow | -4.85M | -11.62M | 29.88M | 8.51M | -7.94M | 42.55M |
KALA BIO Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KALA, the sentiment is Negative. The current price of 0.17 is below the 20-day moving average (MA) of 0.18, below the 50-day MA of 0.35, and below the 200-day MA of 5.59, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 31.55 is Neutral, neither overbought nor oversold. The STOCH value of 61.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KALA.
KALA BIO Risk Analysis
KALA BIO disclosed 67 risk factors in its most recent earnings report. KALA BIO reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksKALA BIO Peers Comparison
Overall Rating
CTXR43Neutral
HIND40Underperform
DARE39Underperform- KALA39Underperform
XCUR38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| CTXR | 43Neutral | $13.53M | -0.23 | -67.15% | ― | ― | 57.48% |
| HIND | 40Underperform | $10.81M | -0.05 | -254.62% | ― | -97.99% | 99.28% |
| DARE | 39Underperform | $13.61M | -0.88 | -748.08% | ― | ― | ― |
| KALA | 39Underperform | $3.31M | -0.00 | -222.32% | ― | ― | 78.25% |
| XCUR | 38Underperform | $7.07M | -0.85 | -237.91% | ― | ― | 23.05% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| KALA | Kala Bio, Inc. | 0.17 | -32.73 | -99.48% | |
| DARE | Daré Bioscience | 0.69 | -1.20 | -63.28% | |
| HIND | Vyome Holdings, Inc. | 1.57 | -3.36 | -68.15% | |
| CTXR | Citius Pharma | 0.48 | -0.53 | -52.48% | |
| LEXX | Lexaria Bioscience Corp. | 4.64 | -11.86 | -71.88% | |
| XCUR | Exicure | 1.11 | -2.54 | -69.60% |
KALA BIO Corporate Events
KALA BIO Stockholders Approve Key Corporate Proposals
NeutralKALA BIO stockholders elected Yonatan Colman and Brendan Purdy as Class III directors to serve until the 2029 Annual Meeting. They also approved, on a nonbinding advisory basis, compensation for the company’s named executive officers.Stockholders rat...
Kala Bio Secures Exclusive Ophthalmic Genetic Testing Deal
PositiveOn September 3, 2026, Kala Bio entered into an Exclusive Distribution and Reseller Agreement with Virotek, Inc., under which Kala became the sole distributor and reseller of Virotek’s genetic testing and clinical screening program for ophthalmology i...
KALA BIO Updates Annual Meeting and Proposal Deadlines
NeutralOn September 9, 2026, KALA BIO’s Board of Directors set November 3, 2026 as the date for the company’s next annual meeting of stockholders, advancing it by more than 30 days from the prior year’s meeting date. The company will later disclose specific...
KALA BIO Faces Nasdaq Listing Compliance Uncertainty
NegativeOn August 27, 2026, KALA BIO disclosed that it received a Nasdaq Staff Determination Letter stating its common stock had closed below $1.00 for 30 consecutive business days from July 16 to August 26, 2026, violating the exchange’s minimum bid price r...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 15, 2026